Analytical Data
-
Gene name
FAAH2
- Application
-
Alternative Names
(Amidase domain-containing protein)(Anandamide amidohydrolase 2)(Oleamide hydrolase 2)
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q6GMR7
-
Expression Region
1-532aa
-
Molecular Weight
59.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FAAH2 (fatty acid amide hydrolase 2) is an important enzyme belonging to the serine hydrolase superfamily, primarily involved in the metabolism of endogenous bioactive lipids, including fatty acid amides such as anandamide, a key endocannabinoid. Research into FAAH2 has gained momentum due to its potential implications in various physiological and pathological processes, including pain modulation, inflammation, and neuroprotection. Unlike its closely related homolog FAAH1, FAAH2 displays distinct substrate specificity and expression patterns, raising interest in its unique roles within the endocannabinoid system. Studies have suggested that variations in FAAH2 activity may correlate with certain neuropsychiatric conditions, obesity, and metabolic disorders. Additionally, understanding the structure and function of FAAH2 could lead to the development of novel therapeutic strategies aimed at modulating endocannabinoid signaling for the treatment of various diseases. As researchers continue to explore the enzyme's biochemistry and its regulatory mechanisms, FAAH2 emerges as a promising target for drug discovery and a better understanding of lipid-mediated signaling pathways in health and disease.
